InPen™ Smart insulin pen

InPen empowers you and your patients with actionable data not available through multiple daily injections (MDI), until now.

Request info

Overview

Intuitive decision support

InPen helps MDI users take the right amount of insulin at the right time, thanks to real-time tracking and decision support.

The InPen smart insulin pen with components labeled.

Humalog® is a registered trademark of Eli Lilly and Company.
Fiasp® and Novolog® are registered trademarks of Novo Nordisk A/S

The InPen app with components labeled.

InPen helps solve common MDI challenges

Insulin vial icon.

Missing 2 doses per week can lead to an increase in A1C of up to 0.4%1

2 out of 3 people icon.

2 out of 3 people need help calculating their doses and 60% of doses are stacked2-4

Personal trend icon.

Lack of accurate dosing data is a barrier to optimizing glycemic control5

Calculator icon.

The use of a bolus calculator is associated with a 0.7-1.0% reduction in A1C6-8

Patient data in one convenient place

Integrated, reliable diabetes data

InPen Insights Reports provide a way to view a patient’s glucose, carbohydrate, and insulin dosing data from their InPen system.

Easy collaboration

InPen Insights Reports help providers assess a patient’s insulin doses and glycemic levels, regardless of which multiple daily injection regimen the patient is following.

InPen insighted report displayed on an iPad
Example patient profile

Pay as little as $35 for the InPen system (terms and conditions apply)

Offer available to those with commercial insurance.
Terms and conditions apply. Learn more here.

A system that helps make life easier for your patients

InPen helps MDI users take the right amount of insulin at the right time, thanks to real-time tracking and decision support

Tracks active insulin

Reminds user to dose

Calculates personalized doses

Automatically logs doses

Syncs with CGMs and glucose meters

 

Learn about a smarter diabetes management tool

Complete the form below and a sales representative will follow up with additional information.

This form is for Healthcare Professionals. If you are a patient looking for more information click here

* Indicates a required field.

Your information will be used and protected in accordance with our privacy statement.

Prescription Information

Frequently asked questions

Expand All

How much does InPen cost?

How do I prescribe InPen?

How do I adjust my patient's therapy mode?

How can I obtain a report from my patient?

Who will teach my patient how to use InPen?

1

Randlov, J., Poulsen, J.U. J Diabetes Sci Technol. 2008 Mar; 2(2): 229-235. Published online 2008 Mar. doi: [10.1177/1932296 80800200209]

2

Garg SK, Bookout TR, McFann KK, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technology and Therapeutics. 2008; 10(5):369-375.

3

Zaugg, Stephanie D., et al. “Diabetes numeracy and blood glucose control: association with type of diabetes and source of care.” Clinical diabetes: a publication of the American Diabetes Association 32.4 (2014): 152-157.

4

Cavanaugh, Kerri, et al. “Association of numeracy and diabetes control.” Annals of Internal Medicine 148.10 (2008): 737-746.

5

Klonoff DC, Kerr D. Smart Pens Will Improve Insulin Therapy. J Dia Sci & Tech, 2018;12(3):551-553.

6

Ziegler R, Cavan DA, Cranston I, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013; 36(11):3613-3619.

7

Kaufman FR, Halvorson M, Carpenter S. Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care. 1999; 22(8):1252-1257.

8

Anderson DG. Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII. Pediatric Diabetes. 2009; 10(5):304-309

IMPORTANT SAFETY INFORMATION FOR INPEN™ SMART INSULIN PEN:

The InPenTM requires a prescription. It is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin. The pen injector is compatible with Lilly Humalog® U-100 3.0 mL cartridges, Novo Nordisk Novolog® U-100 3.0 mL cartridges, and Novo Nordisk Fiasp® U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments.

The InPenTM dose calculator, a component of the InPenTM app, is indicated for the management of diabetes by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for calculating an insulin dose or carbohydrate intake based on user entered data.

For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-specific target blood glucose, insulin-to-carbohydrate ratio, insulin sensitivity parameters, and duration of insulin action to be programmed into the software prior to use as it is required for set up.

For an insulin dose based on fixed/variable meal sizes, a healthcare professional must provide patient-specific fixed doses/meal sizes to be programmed into the software prior to use.

For additional product and important safety considerations, see User Guide and http://bit.ly/InPenSafety.